Summary of Study ST002251
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001439. The data can be accessed directly via it's Project DOI: 10.21228/M8QD9Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002251 |
Study Title | Untargeted metabolomics on plasma from children with asthma, comparing exacerbation-prone to non-exacerbation-prone |
Study Type | Untargeted MS |
Study Summary | Background: Some children with asthma remain poorly controlled and have recurrent exacerbations despite treatment with inhaled corticosteroids. Aside from prior exacerbations, there are currently no reliable predictors of exacerbation-prone asthma in these children and limited understanding of potential underlying mechanisms. Objective: We sought to quantify small molecules in the plasma of children with exacerbation- prone asthma through mass spectrometry-based metabolomics. We hypothesized that the plasma metabolome of these children would differ from that of children with non-exacerbation- prone asthma. Methods: Plasma metabolites were extracted from four pediatric asthma cohorts (n=215 total, n=41 with exacerbation-prone asthma) and detected using a ZIC-HILIC column coupled to a Q Exactive HF mass spectrometer. High-confidence annotations were retained for univariate analysis and were confirmed by a sensitivity analysis in subjects on high-dose inhaled corticosteroids. Metabolites that varied by cohort were excluded. Metaboanalyst was used to identify pathways of interest. Concentrations were calculated by reference standardization to NIST SRM 1950. Results: We identified 32 unique, cohort-independent metabolites that differed in children with exacerbation-prone asthma compared to children with non-exacerbation-prone asthma. Comparison of metabolite concentrations to literature-reported values for healthy children revealed that most metabolites were decreased in both asthma groups, but more so in exacerbation-prone asthma. Pathway analysis identified arginine, lysine, and methionine pathways as most impacted. Conclusions: Several plasma metabolites are perturbed in children with exacerbation-prone asthma and are largely related to arginine, lysine, and methionine pathways. While validation is needed, plasma metabolites may be potential biomarkers for exacerbation-prone asthma in children. |
Institute | Emory University |
Department | Pediatrics |
Laboratory | Joshua Chandler, PhD |
Last Name | Chandler |
First Name | Joshua |
Address | 2015 Upper Gate Drive NE, Atlanta, GA 30322 |
joshua.chandler@emory.edu | |
Phone | 404-727-3536 |
Submit Date | 2022-07-25 |
Num Groups | 2 |
Total Subjects | 215 |
Num Males | 135 |
Num Females | 80 |
Publications | JACI-D-22-00220 |
Raw Data Available | Yes |
Raw Data File Type(s) | mzML |
Analysis Type Detail | LC-MS |
Release Date | 2023-01-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
Analysis ID | AN003677 | AN003678 |
---|---|---|
Analysis type | MS | MS |
Chromatography type | HILIC | HILIC |
Chromatography system | Vanquish Horizon Binary ultrahigh performance liquid chromatography system | Vanquish Horizon Binary ultrahigh performance liquid chromatography system |
Column | SeQuant ZIC-HILIC | SeQuant ZIC-HILIC |
MS Type | ESI | ESI |
MS instrument type | Orbitrap | Orbitrap |
MS instrument name | Thermo Q Exactive HF hybrid Orbitrap | Thermo Q Exactive HF hybrid Orbitrap |
Ion Mode | POSITIVE | NEGATIVE |
Units | peak area | peak area |
MS:
MS ID: | MS003428 |
Analysis ID: | AN003677 |
Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | Data were processed using Compound Discoverer 3.2 (Thermo). Minimum peak intensity was 5E5 for positive mode. Retention times were aligned across runs, quality control (QC) pooled sample areas were normalized per metabolite using a cubic spline method, requiring <50% relative standard deviation after correction for compound retention. Missing values were gap-filled based on real peak detection and metabolites with max sample area <5-fold that of the blank were censored. |
Ion Mode: | POSITIVE |
Capillary Temperature: | 275 |
Ion Spray Voltage: | +3.5 kV |
Automatic Gain Control: | 1E6 |
MS ID: | MS003429 |
Analysis ID: | AN003678 |
Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | Data were processed using Compound Discoverer 3.2 (Thermo). Minimum peak intensity was 2E5 for negative mode. Retention times were aligned across runs, quality control (QC) pooled sample areas were normalized per metabolite using a cubic spline method, requiring <50% relative standard deviation after correction for compound retention. Missing values were gap-filled based on real peak detection and metabolites with max sample area <5-fold that of the blank were censored. |
Ion Mode: | NEGATIVE |
Capillary Temperature: | 275 |
Ion Spray Voltage: | -2.75 kV |
Automatic Gain Control: | 1E6 |